**Core tip:** Selective serotonin reuptake inhibitor (SSRI) users were associated with a risk of subsequently diagnosed irritable bowel syndrome. The brain-gut axis may play a key role in this relationship. In clinical practice, physicians should pay attention to the gastrointestinal symptoms of patients with psychiatric disorders and SSRI use.

INTRODUCTION
============

Antidepressants are among the most widely used medications in clinical practice for the treatment of depressive disorder, panic disorder, generalized anxiety disorder, and numerous other psychiatric diseases\[[@B1],[@B2]\]. Among the many classes of antidepressants, selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed because of their effectiveness in treating many psychiatric disorders. SSRIs are safer and have a more favorable side-effect profile than the previous generations of antidepressants\[[@B3]\]. However, numerous studies have indicated that short-term use of SSRIs can cause many adverse side effects, including nausea, diarrhea and unstable mood swings. Additionally, suicide attempts, gastrointestinal bleeding, sexual dysfunction, and hyponatremia may occur during long-term use\[[@B4]-[@B6]\].

Irritable bowel syndrome (IBS) is part of a large group of functional gastrointestinal disorders that are characterized by recurrent abdominal discomfort or pain and disturbed defecation in the absence of organic disease\[[@B7],[@B8]\]. IBS is one of the most commonly treated diseases by primary care physicians as well as gastroenterologists. The prevalence of IBS is estimated to be 7.5%-21% worldwide\[[@B9],[@B10]\]. IBS is a functional disorder and has no contribution towards mortality\[[@B11]\]; however, it is chronic and significantly reduces patients' quality of life\[[@B9],[@B12],[@B13]\]. The suggested treatments for IBS include antispasmodics, antidiarrheal agents, laxatives, prokinetics, probiotics, anxiolytics, SSRIs, tricyclic antidepressants (TCAs), 5-HT3 antagonists, cGMA agonists, and antibiotics according to each patient's clinical symptoms\[[@B14],[@B15]\]. However, there is no universally accepted or recommended therapy that effectively cures this disease.

The pathophysiology of IBS is believed to be associated with abnormal gastrointestinal motility, visceral hypersensitivity, low-grade inflammation, stress and brain-gut interactions\[[@B9],[@B16]\]. Additionally, a high prevalence of psychiatric disorders in patients with IBS, in particular anxiety and depressive disorders, has been reported in previous studies\[[@B16],[@B17]\]. Antidepressants are often used to treat a variety of functional bowel disorders. Tricyclic antidepressants have been proven to offer statistically significant control of IBS symptoms in a previous meta-analysis\[[@B18],[@B19]\]. Additionally, several randomized controlled trials have evaluated the safety and efficacy of fluoxetine, citalopram and paroxetine for the treatment of IBS\[[@B20]-[@B23]\]. However, the evidence regarding the effectiveness of SSRIs in providing symptom relief in IBS is inconsistent. The American Gastroenterological Association Institute guidelines advise against using SSRIs for patients with IBS, based on the lack of improvement in global relief of symptoms identified in pooled estimates of five randomized control trials\[[@B24]\].

The present study aimed to explore the relationship of SSRIs with the subsequent development of IBS using the Taiwan National Health Insurance Research Database (NHIRD).

MATERIALS AND METHODS
=====================

Data source
-----------

The database used in our study was the NHIRD of Taiwan. The National Health Insurance (NHI) program in Taiwan was initiated in 1995 and enrolled over 24 million people by the end of 2014, representing 99% of the population in Taiwan. In the present study, data from the Longitudinal Health Insurance Database (LHID) 2000 were analyzed. The LHID 2000 is a subset of the NHIRD that contains data from 1000000 randomly sampled patients, which is approximately 5% of the Taiwan's general population. We conducted a retrospective observational study on the correlation of SSRIs with and their possible influence on IBS. This study was approved by the Institutional Review Board (IRB) of Taichung Veterans General Hospital (IRB number: CE13152B-3), and because the data were obtained from the LHID 2000, informed consent from the participants was not obtained. The IRB specifically waived the requirement for consent.

Study population
----------------

We extracted data from the LHID 2000 for this retrospective study. Patients with a more than two-month medical prescription for an SSRI during one year between January 1, 2000 and December 31, 2010 were selected. The prescribed SSRIs included fluoxetine, citalopram, paroxetine, sertraline, fluvoxamine and escitalopram. We excluded any patients who were diagnosed with IBS (ICD-9-CM code: 564.1) prior to medical treatment with SSRIs. The comparison cohort included patients without any medical history of SSRI use who were frequency-matched with the SSRI cohort by age, sex, index date and year at a ratio of 1:4 (Figure [1](#F1){ref-type="fig"}). To ensure the validity of the diagnosis, we included only patients who were diagnosed with IBS (ICD-9-CM code: 564.1) in more than three outpatient visits or more than one inpatient hospitalization. The included patients taking SSRIs were regularly followed at the database for at least three outpatient visits. Thus, we supposed that these patients needed these medication, and had compliance in medication.

![Flowchart of study design. IBS: Irritable bowel syndrome; LHID: Longitudinal Health Insurance Database; SSRI: Selective serotonin reuptake inhibitor.](WJG-23-3513-g001){#F1}

In addition, patients with inflammatory bowel disease (ICD-9:555, 556) were excluded because some of these patients exhibit symptoms similar to those of IBS during the inactive or remission stage of inflammatory bowel syndrome\[[@B25]-[@B29]\]. Additionally, patients with a diagnosis of infectious enterocolitis (ICD 9: 0078,0079, 0080-0088, 0090-0093, 558, 0030, 0062, 11285) within three months prior to the diagnosis of IBS were excluded due to the potentially increased risk of post-infectious IBS associated with bacterial, protozoan, helminth, or viral infections, all of which have been reported\[[@B30]-[@B34]\]. The main outcome was the incidence of newly diagnosed IBS during the follow-up period, which was estimated as the duration from the index date until IBS, withdrawal from the insurance system, or the end of study in 2011.

Furthermore, common comorbidities diagnosed before enrollment in this study, including hypertension, diabetes mellitus, dyslipidemia, colorectal cancer, major depressive disorder, anxiety disorder, bipolar disorder, and posttraumatic disorder, were compared between the SSRI and comparison cohorts.

Statistical analysis
--------------------

All analyses were performed using SAS software, version 9.3 (SAS Institute, Cary, NC, United States). The distributions of SSRI exposure based on subject's age, gender and clinical comorbidities were examined using *χ*^2^ tests for categorical variables.

In the cohort study, multivariable Cox proportional hazard models were used to explore the relationship between exposure to SSRI and the diagnosis of IBS, after adjusting for age, gender and medical comorbidities. All statistical tests were two-sided, conducted at a signiﬁcance level of 0.05, and reported using *P* values and/or 95%CIs.

RESULTS
=======

Demographic characteristics of study subjects
---------------------------------------------

The eligible study participants included 19653 patients in the SSRI cohort and 78612 persons in the comparison cohort, with a similar age and sex distribution (Figure [1](#F1){ref-type="fig"} and Table [1](#T1){ref-type="table"}). Males represented 41.5% and females 58.5% of the entire study population. The mean follow-up time in the present study was 5.9 ± 3.0 years in the non-SSRI cohort and 5.5 ± 3.2 years in the SSRI cohort. The mean follow-up period of SSRI exposure to IBS diagnosis was 2.05 years. The majority of psychiatric disorders leading to a prescription of SSRI included anxiety (48.2%) and major depressive disorders (21.8%). There was more concomitant anti-psychotic usage in the SSRI cohort than in the non-SSRI group. However, most participants in both groups did not use anti-psychotics.

###### 

Baseline characteristics of the selective serotonin reuptake inhibitor cohort and the non-selective serotonin reuptake inhibitor cohort, 2000-2010 *n* (%)

  **Variable**                                   **SSRI use**   ***P* value**   
  ---------------------------------------------- -------------- --------------- ----------
  Sex                                                                           1.000
  Female                                         45984 (58.5)   11496 (58.5)    
  Male                                           32628 (41.5)   8157 (41.5)     
  Age, yr                                                                       1.000
  \< 20                                          5548 (7.1)     1387 (7.1)      
  20-29                                          11592 (14.8)   2898 (14.8)     
  30-39                                          14312 (18.2)   3578 (18.2)     
  40-49                                          15112 (19.2)   3778 (19.2)     
  50-59                                          11720 (14.9)   2930 (14.9)     
  ≥ 60                                           20328 (25.9)   5082 (25.9)     
  Urbanization[1](#T1FN1){ref-type="table-fn"}                                  \< 0.001
  1                                              24102 (31.3)   6275 (32.7)     
  2                                              23134 (30.0)   5851 (30.5)     
  3                                              12486 (16.2)   2827 (14.7)     
  4                                              17325 (22.5)   4228 (22.0)     
  Family income (NTD)                                                           \< 0.001
  0                                              13932 (17.7)   3411 (17.4)     
  1-15840                                        14871 (18.9)   4807 (24.5)     
  15841-28800                                    33687 (42.9)   7915 (40.3)     
  28801-45800                                    10243 (13.0)   2173 (11.1)     
  ≥ 45801                                        5874 (7.5)     1346 (6.9)      
  Area                                                                          \< 0.001
  North                                          39708 (50.6)   10001 (51.0)    
  Midland                                        14067 (17.9)   3265 (16.7)     
  South                                          22823 (29.1)   5642 (28.8)     
  East                                           1837 (2.3)     690 (3.5)       
  Occupation                                                                    \< 0.001
  Public and military                            5735 (8.2)     1531 (8.8)      
  Industry                                       23168 (33.3)   5617 (32.3)     
  Business                                       28266 (40.6)   5841 (33.6)     
  Low income                                     559 (0.8)      385 (2.2)       
  Other and retired                              11898 (17.1)   3994 (23.0)     
  Anti-psychotics                                                               \< 0.001
  No                                             75615 (96.2)   16022 (81.5)    
  Yes                                            2997 (3.8)     3631 (18.5)     
  Comorbidity                                                                   
  Diabetes mellitus                              8126 (10.3)    3143 (16.0)     \< 0.001
  Hypertension                                   18319 (23.3)   6726 (34.2)     \< 0.001
  Hyperlipidemia                                 11823 (15.0)   4521 (23.0)     \< 0.001
  Colorectal cancer                              290 (0.4)      96 (0.5)        0.017
  Major depressive disorder                      770 (0.98)     4274 (21.8)     \< 0.001
  Anxiety disorder                               10007 (12.7)   9477 (48.2)     \< 0.001
  Bipolar disorder                               130 (0.2)      273 (1.4)       \< 0.001
  Posttraumatic stress disorder                  7 (0.0)        101 (0.5)       \< 0.001
  Eating disorder                                26 (0.0)       141 (0.7)       \< 0.001
  Mean follow-up time (yr)                       5.86 ± 3.00    5.53 ± 3.21     

Urbanization level: 1 indicates the highest level of urbanization and 4 the lowest. SSRI: Selective serotonin reuptake inhibitor; NTD: New Taiwan dollars.

At the baseline, comorbid diabetes, hypertension, hyperlipidemia, colorectal cancer, major depressive disorder and anxiety disorder were more prevalent in the SSRI cohort than in the comparison cohort.

Risk of IBS in SSRI users
-------------------------

A total of 236 patients in the SSRI cohort (incidence, 2.17/1000 person-years) and 478 patients in the comparison cohort (incidence, 1.04/1000 person-years) had a new diagnosis of IBS during the follow-up period (Table [2](#T2){ref-type="table"}). The incidence of IBS increased with advancing age. Comorbidities such as diabetes mellitus, hypertension, hyperlipidemia, colorectal cancer, and major depressive disorder did not influence the HR of IBS. However, patients with anxiety disorders had a significantly increased HR of IBS (HR = 1.33, 95%CI: 1.11-1.59, *P =* 0.002). The use of anti-psychotics did not affect the incidence of IBS, whereas the use of SSRIs was associated with an increased HR of IBS.

###### 

Comparisons of the incidence of irritable bowel syndrome by age, gender, comorbidity and drug use

  **Variable**                **Events**   **PT**   **Rate[1](#T2FN1){ref-type="table-fn"}**   **HR[2](#T2FN2){ref-type="table-fn"}**   **(95%CI)**   ***P* value**
  --------------------------- ------------ -------- ------------------------------------------ ---------------------------------------- ------------- ---------------
  Sex                                                                                                                                                 
  Female                      414          335363   1.23                                       1.00                                     (reference)   
  Male                        300          233656   1.28                                       1.05                                     (0.91-1.23)   0.495
  Age, yr                                                                                                                                             
  \< 20                       13           43139    0.30                                       1.00                                     (reference)   
  20-29                       47           91408    0.51                                       1.62                                     (0.87-3.01)   0.128
  30-39                       93           110721   0.84                                       2.52                                     (1.40-4.55)   0.002
  40-49                       153          113198   1.35                                       3.94                                     (2.22-7.02)   \< 0.001
  50-59                       133          80752    1.65                                       4.56                                     (2.54-8.17)   \< 0.001
  ≥ 60                        275          129801   2.12                                       5.57                                     (3.12-9.92)   \< 0.001
  Comorbidity (yes *vs* no)                                                                                                                           
  Diabetes mellitus           113          55858    2.02                                       0.93                                     (0.74-1.17)   0.549
  Hypertension                269          129073   2.08                                       1.06                                     (0.87-1.28)   0.576
  Hyperlipidemia              175          84352    2.07                                       1.07                                     (0.88-1.31)   0.482
  Colorectal cancer           5            1527     3.27                                       1.48                                     (0.61-3.58)   0.386
  Major depressive disorder   67           30292    2.21                                       1.19                                     (0.90-1.57)   0.217
  Anxiety disorder            220          96735    2.27                                       1.33                                     (1.11-1.59)   0.002
  Bipolar disorder            5            2435     2.05                                       1.03                                     (0.42-2.52)   0.820
  Anti-psychotics                                                                                                                                     
  No                          630          535264   1.18                                       1.00                                     (reference)   
  Yes                         84           33755    2.49                                       1.18                                     (0.92-1.50)   0.193
  SSRIs                                                                                                                                               
  No                          478          460307   1.04                                       1.00                                     (reference)   
  Yes                         236          108713   2.17                                       1.74                                     (1.44-2.10)   \< 0.001

Per 1000 person-years;

Adjusted by age, sex, urbanization, family income, area of residence, occupation, anti-psychotics and the comorbidities listed in Table [1](#T1){ref-type="table"}. IBS: Irritable bowel syndrome; SSRIs: Selective serotonin reuptake inhibitors.

Incident rate and HR of IBS associated with SSRI use in Cox regression analyses
-------------------------------------------------------------------------------

After adjusting for sex, age and other comorbidities including diabetes, hypertension, hyperlipidemia and colorectal cancer, the overall adjusted HR (aHR) in the SSRI cohort compared with the comparison cohort was 1.74 (95%CI: 1.44-2.10; *P \<* 0.001) using Cox regression analysis. The subgroup analysis showed that the aHR was higher in SSRI users than in non-SSRI users among females (aHR = 1.65; 95%CI: 1.29-2.11), males (aHR = 1.85; 95%CI: 1.38-2.48) and individuals aged between 20 and 60 years (Table [3](#T3){ref-type="table"}).

###### 

Incidence rate and hazard ratio of irritable bowel syndrome associated with selective serotonin reuptake inhibitor use in Cox regression analysis

            **SSRI use (2000-2010)**   **aHR[2](#T3FN2){ref-type="table-fn"}**   **(95%CI)**   ***P* value**                                        
  --------- -------------------------- ----------------------------------------- ------------- --------------- -------- ------ ------ ------------- ----------
  Overall   478                        460307                                    1.04          236             108713   2.17   1.74   (1.44-2.10)   \< 0.001
  Sex                                                                                                                                               
  Female    282                        270195                                    1.04          132             65169    2.03   1.65   (1.29-2.11)   \< 0.001
  Male      196                        190112                                    1.03          104             43544    2.39   1.85   (1.38-2.48)   \< 0.001
  Age                                                                                                                                               
  \< 20     8                          34575                                     0.23          5               8564     0.58   1.12   (0.23-5.41)   0.884
  20-29     27                         73594                                     0.37          20              17815    1.12   2.78   (1.36-5.70)   0.005
  30-39     61                         89305                                     0.68          32              21416    1.49   1.95   (1.13-3.34)   0.016
  40-49     96                         91299                                     1.05          57              21899    2.60   1.79   (1.19-2.69)   0.005
  50-59     85                         65244                                     1.30          48              15508    3.10   2.17   (1.40-3.36)   \< 0.001
  ≥ 60      201                        106290                                    1.89          74              23511    3.15   1.32   (0.97-1.79)   0.077

per 1000 person-years;

aHR, adjusted by age, sex, urbanization, family income, area of residence, occupation, anti-psychotics and the comorbidities listed in Table [1](#T1){ref-type="table"}. IBS: Irritable bowel syndrome; SSRI: Selective serotonin reuptake inhibitor.

The cumulative incidence of IBS was higher in the SSRI cohort than in the non-SSRI cohort (log-rank test, *P* \< 0.001) (Figure [2](#F2){ref-type="fig"}).

![Comparison of the cumulative incidence of irritable bowel syndrome for selective serotonin reuptake inhibitor users and non-users. SSRI: Selective serotonin reuptake inhibitor; IBS: Irritable bowel syndrome.](WJG-23-3513-g002){#F2}

HR of IBS associated with the duration of SSRI exposure
-------------------------------------------------------

Table [4](#T4){ref-type="table"} shows the association between SSRI exposure days over one year and the HR of a subsequent diagnosis of IBS. The aHR was highest in individuals with a one-year SSRI exposure of less than 90 d (aHR = 3.27, 95%CI: 2.61-4.08). The aHR remained significantly higher in patients with longer durations of SSRI exposure.

###### 

Hazard ratio of irritable bowel syndrome associated with duration of selective serotonin reuptake inhibitor exposure over one year

                            **aHR[1](#T4FN1){ref-type="table-fn"}**   **(95%CI)**   ***P* value**
  ------------------------- ----------------------------------------- ------------- ---------------
  SSRI non-users            1.00                                      (reference)   
  SSRI exposure \< 90 d     3.27                                      (2.61-4.08)   \< 0.001
  SSRI exposure 90-180 d    1.38                                      (1.03-1.85)   0.029
  SSRI exposure 181-270 d   1.49                                      (1.05-2.13)   0.027
  SSRI exposure ≥ 270 d     1.52                                      (1.07-2.15)   0.020

aHR, adjusted by age, sex, urbanization, family income, area of residence, occupation, anti-psychotics and the comorbidities listed in Table [1](#T1){ref-type="table"}. SSRI: Selective serotonin reuptake inhibitor.

Hazard ratio of IBS among SSRI and antidepressant users
-------------------------------------------------------

A subgroup analysis of SSRI and non-SSRI users showed a significantly increased aHR of IBS in SSRI only users (aHR = 1.82, 95%CI: 1.50-2.21, *P* \< 0.001) but not in the users of other antidepressants only (aHR = 1.33, 95%CI: 0.75-2.36, *P* = 0.338) or the combined SSRI and other antidepressant users (aHR = 1.30, 95%CI: 0.84-2.01, *P* = 0.235) (Table [5](#T5){ref-type="table"}).

###### 

Hazard ratio of irritable bowel syndrome among selective serotonin reuptake inhibitor and antidepressant users

                                      ***n***   **aHR[1](#T5FN1){ref-type="table-fn"}**   **(95%CI)**   ***P* value**
  ----------------------------------- --------- ----------------------------------------- ------------- ---------------
  Overall                                                                                               
  Non-SSRIs                           77327     1.00                                      (reference)   
  Non-SSRIs + other antidepressants   1285      1.33                                      (0.75-2.36)   0.338
  SSRIs + other antidepressants       2872      1.30                                      (0.84-2.01)   0.235
  SSRIs only                          16781     1.82                                      (1.50-2.21)   \< 0.001

aHR, adjusted by age, sex, urbanization, family income, area of residence, occupation, anti-psychotics and the comorbidities listed in Table [1](#T1){ref-type="table"}. SSRIs: Selective serotonin reuptake inhibitors.

DISCUSSION
==========

Based on our review of the literature, this is the first study using nationwide population database to investigate the relationship between SSRI prescriptions and IBS in Taiwan. Our results revealed that patients exposed to SSRIs had an increased risk of developing IBS (aHR = 1.74) after adjusting for sex, age, and major comorbidities.

In this study, we demonstrated that IBS in SSRI users tended to occur in older patients. The incidence of IBS became higher as age increased in both SSRI users and non-users, and this finding conflict with both the global data and a previous questionnaire survey conducted in Taiwan\[[@B10],[@B35]\]. A previous global meta-analysis and questionnaire study in Taiwan showed that the prevalence of IBS decreased with advancing age. However, the participants in the previous questionnaire study in Taiwan were healthy volunteers, and thus the prevalence of IBS in the Taiwan's general population may have been underestimated. Additionally, IBS symptoms may occur at early ages with relatively benign symptoms. Most patients may tolerate these symptoms and not seek medical advice; this tendency may have also led to an underestimation of the incidence of IBS in young individuals.

To evaluate the dose effect of SSRIs on the subsequent development of IBS, we analyzed the days of SSRI exposure within one year and determined the HR of subsequent IBS diagnosis. The aHR was highest in individuals with SSRI exposure for less than 90 d but remained significantly higher for patients with longer exposure times. Although SSRIs include widely used antidepressants that are more tolerable and have relatively benign adverse effects compared to TCAs or monoamine oxidase inhibitors\[[@B3]\], they continue to have some early onset adverse effects and problems associated with long-term treatment. The early onset adverse effects include gastrointestinal discomfort, nausea, dyspepsia and diarrhea and disappear within two to three weeks\[[@B5]\]. The higher HR of IBS in individuals with lower SSRI exposure times may be due to these early onset gastrointestinal side effects that lead to misdiagnosis of IBS by clinical physicians. However, Table [4](#T4){ref-type="table"} shows that patients with SSRI exposure for more than 90 d had a significantly higher HR of IBS, and this finding cannot be explained by the early gastrointestinal adverse effects of SSRIs. In addition, the mean follow-up time from SSRI exposure to IBS diagnosis was 2.05 years, which is long enough to exclude transient adverse effects of SSRIs. Therefore, it can be hypothesized that the long duration of psychiatric disorders leads to an increased risk of subsequent IBS.

Many studies have identified a relationship between IBS and psychiatric disorders\[[@B17],[@B36]\]. In patients with IBS who seek treatment, the rates of comorbid psychiatric disorders range from 54% to 94%\[[@B9],[@B12]\]. Anxiety and depression disorders are associated with gastrointestinal symptoms in accordance with brain-gut interactions\[[@B37]-[@B40]\]. Additionally, the communication between the central nervous system and enteric nervous system appears to be bidirectional\[[@B36]\]. The biopsychological model of IBS suggests that deterioration of gastrointestinal symptoms could exacerbate anxiety and depression (bottom-up model) and that psychological factors themselves similarly influenced physiological factors (top-down model)\[[@B41]\]. Fond et al\[[@B17]\] demonstrated in a systematic review and meta-analysis that patients with IBS have significantly higher levels of anxiety and depression than healthy controls. To exclude the influence of other antidepressants, we performed a subgroup analysis of SSRI and non-SSRI users. Table [5](#T5){ref-type="table"} shows that the aHR was significantly higher in the users of SSRIs only compared with the users of non-SSRIs or users of combined SSRIs and other antidepressants. The use of other antidepressants only or in combination with SSRIs was not associated with an increased risk of IBS.

One possible reason for the higher incidence of IBS in the SSRI cohort is that the patients' underlying psychiatric disorders, particularly anxiety, may have deteriorated and thus their subclinical gastrointestinal symptoms became overt. Under these conditions, clinical physicians may provide new prescriptions for SSRIs, and patients may seek medical advice for IBS symptoms. This process is consistent with our study results, which showed that patients with anxiety disorders had a significantly higher HR of IBS. Poorly controlled anxiety disorders and unstable mood may exacerbate the symptoms of IBS. The increased HR of IBS in the SSRI cohort, compared with the comparison cohort in our study, may be due to the increased severity of anxiety disorders, poor compliance to SSRIs due to adverse medication effects or personal reasons.

There were some limitations to our study. First, there is only one code for IBS (ICD-9-CM code: 564.1) in the ICD-9 system, and further subgroup analyses were therefore not feasible. Second, data on lifestyle factors, such as smoking and alcohol use, were not available in the NHIRD. Third, information on drug compliance was not obtained from this health care database. Fourth, the severity of any psychiatric disorder upon enrollment in the study was also not available in the NHIRD. Fifth, there are always coding issues in database studies. There may be registration differences among the physicians and psychiatrists who did not code for IBS and the gastroenterologists who did not code for depression/anxiety. However, most physicians should adhere to the proper coding standards due to NHI payment rules.

In conclusion, SSRI use is associated with subsequently diagnosed IBS. In clinical practice, it is important to pay attention to the gastrointestinal symptoms of patients with psychiatric disorders who use SSRIs.
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